Study: NCT02964013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vibostolimab
Description: Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vibostolimab
Description: Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vibostolimab
Description: Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vibostolimab
Description: Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab/vibostolimab coformulation
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab/vibostolimab coformulation
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4